IMPORTANCE Genome-wide investigations provide systematic information regarding the neurobiology of psychiatric disorders.
nents of that variance.
Rare variants of large effect, such as copy number variants, have been suggested to play a role in BP susceptibility. 7 Although such variants seem unlikely to be as prominent in BP as they appear to be in autism and schizophrenia, this area requires additional investigation. Genomic methods such as sequencing and methylation studies have been used in BP, but no definitive results are yet available.
In addition to specific single genes related to BP, panels of single-nucleotide polymorphisms (SNPs) that contain predictive value for BP have been identified. 8 Allele scoring methods have shown significant similarity not only between independent data sets of patients with BP but also between the genetic architectures of schizophrenia and BP. 9 It has previously been demonstrated that additional information may be gleaned from GWAS by identifying biological pathways. Torkamani et al 10 took this approach in BP; their analysis of Wellcome Trust Case Control Consortium data using the program Metacore, which weights each gene based on the most significant SNP in that gene, suggested 5 pathways, including glutamate regulation of dopamine signaling and adrenergic mediation of cytoskeletal remodeling. Holmans et al 11 applied the method ALIGATOR (Association List Go Annotator; based on overrepresentation of pathway genes in lists of nominally significant SNPs) to Psychiatric Genomics Consortium 1 (PGC1) data on BP; using Gene Ontology (GO) categories, they identified hormonal action, transcriptional regulation, and autophagy as important in BP. O'Dushlaine et al 12 used the SNP ratio test (the ratio of nominally significant to nonsignificant SNPs in genes from a particular pathway) applied to Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways to identify cell adhesion molecules as likely to be involved in BP. Pedroso et al 13 used genewise analysis of 3 GWAS data sets combined with brain expression data to identify specific genes of interest; they separately identified gene sets involved in particular protein interaction subnetworks, specifying association with networks involved with neural transmission, Wnt signaling, and Notch signaling. Le-Niculescu et al 14 used convergent functional genomics, which combines GWAS data with brain expression data and animal model results. Their results emphasize growth factors, neurotransmitters, clock genes and transcription factors, neuronal metabolism, and neuronal connectivity as central mechanisms in BP. In the article by the Psychiatric GWAS Consortium Bipolar Disorder Working Group, 4 pathway analysis identified a group of calcium channel subunits as being putatively involved in BP vulnerability. Our study differs from these in some or all of the following ways: (1) targets genes that show modest but consistent evidence of association across multiple individual data sets; (2) uses an empirical function to correct for gene size; (3) uses the extensively curated Ingenuity database of canonical pathways; (4) uses the gene set enrichment analysis (GSEA)-SNP method for pathway verification; and (5) compares results with gene expression results from an independent study of postmortem dorsolateral prefrontal cortex (DLPFC) from patients with BP. We used 4 individual GWAS data sets for our initial sample and an independent collection of samples from the PGC as a replication data set. To study brain-relevant pathophysiology of BP, we integrated a meta-analysis of gene expression studies from the Stanley Medical Research Institute (SMRI) microarray collection 15 with the results of pathway analysis.
Methods

Association Studies
Ascertainment and Assessment Each of the 4 individual data sets has been previously described and GWAS results have been published. 2, 3, 16, 17 Recruitment and screening of participants have been described for the Genetic Association Information Network, 16 
Pathway Identification
The final list of 226 genes was run on a standard Ingenuity Pathway Analysis (Ingenuity Systems Inc). All canonical pathways with a nominal significance of P < .05 were included in subsequent analyses. Genes driving the pathway results are those in the list of 226 that overlap with the predesignated list of genes in each Ingenuity canonical pathway.
Pathway Testing
Canonical pathways identified in the Ingenuity Pathway Analysis were tested in an independent replication data set composed of samples in PGC2 (all PGC2 data sets with complete GWAS information reported by the Psychiatric GWAS Consortium Bipolar Disorder Working Group 4 plus the Thematically Organized Psychosis Sample 7 data set). Imputation to generate a common SNP map for the PGC2 studies was performed using Impute 20 and the Markov Chain Haplotyping (MACH) algorithm 21 to provide a final data set of 2.5 million SNPs. For computational tractability, a subset of these SNPs corresponding to the Affymetrix version 6.0 platform was used for further analyses. Pathway testing was performed using the GSEA-SNP method, 22 which compares the rank order of the set of SNPs in the genes of the pathway among all SNPs in the PGC2 GWAS results with the null rank order distribution. A significant shift in the rank order pattern was considered evidence of association at the pathway level. The false discovery rate (FDR) was estimated against a general pathway set including pathways from GO, KEGG, and other sources. In each case, the individual Ingenuity pathway of interest was included in the general pathway set to calculate the q value.
Gene Expression in DLPFC of Patients With BP
A prior meta-analysis 15 of DLPFC (Brodmann area 46) samples using the SMRI microarray collection was queried for expression differences in BP samples as compared with controls (https://www.stanleygenomics.org/). The SMRI microarray collection was conducted using the same 105 DLPFC RNA samples (extracted at SMRI) and then processed at 6 independent laboratories by microarray analysis. The demographic and sample characteristics for respective BP cases and controls are as follows: n = 34 and 35; 16 (47.1%) and 26 (74.3%) male; mean (SD) age, 44.1 (7.7) and 45.4 (10.7) years; mean (SD) postmortem interval, 38.6 (18.2) and 29. 4 (12.9) hours; and mean (SD) pH, 6.4 (0.3) and 6.6 (0.3) . Before meta-analysis of individual genes, quality-control filters based on Affymetrix metrics and principal component analysis were used to remove statistical outliers. Both withinand cross-study normalizations were used such that the median expression value for each study was equal to 100. In the meta-analysis, expression was compared between BP and controls using linear regression models on a gene-by-gene basis adjusting for the demographic terms that met the criteria for significance for that gene (pH, sex, age, RNA quality, postmortem interval, disease severity, drug use, smoking, and other covariates [up to 23 demographic effects]). The fold change and P values for each gene were condensed, when appropriate, from multiple probe sets on the microarray platforms by using all probes from each microarray study independently. The consensus fold changes and associated 95% confidence intervals and P values were reported as a weighted combination of the individual fold changes and standard errors of the 6 studies. From this differential expression meta-analysis of the 6 gene expression studies, there were 919 genes nominally significant in BP compared with controls after adjustment for covariates.
A step-by-step summary of the methods is included in the eBox in the Supplement.
Results
From the 4 data sets in our initial sample (Table 1) , we identified 966 genes with at least 2 SNPs at P < .05 in at least 3 of 4 data sets. Simulation was performed on 25 individual genes using simulated data sets representing each of these 4. Results of the simulation are shown in the eTable in the Supplement, and the resulting regression function is shown in eFigure 1 in the Supplement. Using this regression model, 226 empirically significant genes were detected and chosen for the pathway gene set analysis (Box). By application of the binomial theorem (and an estimate of 20 000 genes in the human genome), we would expect that 11 of these 226 genes are likely to be false positives (a proportion of 0.048) and the others are likely to be true positives.
The pathway analysis identified 17 nominally significant canonical pathways ( Table 2 and Table 3 ). These were tested in a replication data set by GSEA along with the total number of genes in each of the pathways of interest. Of the 17 pathways, 6 showed significant association: corticotropinreleasing hormone (CRH) signaling, cardiac β-adrenergic signaling, phospholipase C (PLC) signaling, glutamate receptor signaling, endothelin 1 signaling, and cardiac hypertrophy signaling. The 6 significant pathways are shown in Table 2 and in eFigures 2-7 in the Supplement, with the identified genes highlighted.
It was observed that the 6 significant pathways were tagged in the Ingenuity data set by only 16 of the 226 genes (Box and  Table 4 ): ARHGEF3, CREBBP, GNG2, ITPR2, PLCG2, PLD1, AKAP12, CACNA1C, PDE7B, PPP2R5E, GRM1, GRM7, GLI3, MEF2C, PLA2R1 , and PLCE1. Many of these genes were present in multiple pathways. Because each of these pathways was tagged by multiple genes and because every SNP in every gene in each pathway was tested by GSEA in an independent data set, we do not expect that any of the 6 pathways is a false positive.
The list of 226 genes was compared with the list of 919 genes that differed in expression between DLPFC samples from patients with BP and controls. Nine genes were found to overlap: CACNA1C, DTNA, FOXP1, GNG2, ITPR2, LSAMP, NPAS3, NCOA2, and NTRK3 (Box) . We note that 3 of these genes are also in the list of 16 genes driving the pathway results described earlier (GNG2, CACNA1C, and ITPR2). The concordance of 3 genes in the 2 lists is greater than would be expected by chance (odds ratio observed/expected > 4.43, goodness-of-fit χ 2 P < .005). If we restrict the list of 919 braindysregulated genes to those meeting FDR criteria (n = 26) and then test for overlap with the 226 genes from GWAS, the single gene in the 2 lists is CACNA1C.
Discussion
Using GWAS results from a large sample of patients with BP with full genome-wide SNP data and imputation (a total of 8760 independent cases and 11 763 independent controls), we identified 6 significantly overrepresented pathways: glutamate receptor signaling, PLC signaling, CRH signaling, endothelin 1 signaling, cardiac β-adrenergic signaling, and cardiac hypertrophy signaling ( Table 2 ). All of these pathways involve signaling, including G proteins and second messenger systems, and all except 1 (cardiac β-adrenergic signaling) involve nuclear gene regulation. The pathway with the strongest evidence statistically is the CRH signaling pathway. The GSEA-SNP analysis also showed the highest proportion of pathway genes significantly overrepresented in GWAS results in this pathway (61.5%).
Box. List of 226 Genes or Loci Associated With Bipolar Disorder at Empirical P<.05
Gene names in bold are those genes driving the pathway results; gene names underlined are those genes also significant in the gene expression studies. 1, SATB2, SEMA3C, SEMA5A, SEZ6L, SGCG, SGMS1, SHANK2, SIAH3, SIK3, SLC10A7, SLC2A13, SLIT3, SMG6, SNTB1, SNX29, SORCS2, SPATS2L, SPTLC3, SRGAP3, ST7, STK24, STK4, SYN3, SYNE1, SYT14, tcag7.1213, TCF7L1, THSD4, THSD7A, TMEM108, TRDN, TRPV3, TS-PAN18, TULP4, ULK4, VAT1L, VAV3, WDFY4, WDR72, ZCCHC17, ZNF236, ZNF385B Copyright 2014 American Medical Association. All rights reserved.
These canonical pathways provide independently defined, functionally clustered sets of genes. We have highlighted (1) genes driving the pathway results and (2) genes implicated in studies of brain gene expression.
The genes driving the pathway results (n = 16) are listed in Table 4 . They include 3 genes with dysregulated expression in BP frontal cortex: CACNA1C, GNG2, and ITPR2. They also include DTNA (dystrobrevin, part of the dystrophin complex), FOXP1 (forkhead box transcription factor, involved in language impairment), LSAMP (limbic system-associated membrane protein, involved in cell adhesion), NPAS3 (transcription factor involved in neurogenesis), NCOA2 (activates nuclear hormone receptors), and NTRK3 (neurotrophic tyrosine receptor kinase, involved in neuron migration).
The CRH signaling pathway is an index of the hypothalamicpituitary-adrenal system (eFigure 2 in Supplement). This stressresponsive system is consistently dysregulated in studies of mood disorder. Well-described hypothalamic-pituitaryadrenal abnormalities associated with mood disorders include increased secretion of cortisol over 24 hours 23 and decreased suppression of cortisol by dexamethasone in about 50% of patients with major depressive disorder 24 and specifically in BP.
25
Increased plasma cortisol responses to the dexamethasone/ CRH test have been associated with euthymic BP. 26 Molecules driving this pathway include PLC γ, inositol trisphosphate (IP3) receptor, and myocyte enhancer factor 2 as well as the transcription factor GLi3, which has notable influence on development and is also involved in corticotropin synthesis. The cardiac β-adrenergic signaling pathway (eFigure 3 in Supplement) and the cardiac hypertrophy signaling pathway (eFigure 7 in Supplement) are both driven by the presence of an L-type calcium channel along with G-protein-coupled second messenger systems. L-type calcium channels have been 
Gene Function
CREBBP
Transcription factor
GNG2
Guanine nucleotide binding protein
ITPR2
IP3 receptor
PLCG2
Production of IP3 and DAG
PLD1
Phospholipase producing choline
AKAP12
Anchor/scaffold protein, binds PKA
CACNA1C
Calcium channel subunit
PDE7B
Downregulation of cAMP and cGMP
PPP2R5E
Protein phosphatase
GRM1
Glutamate receptor involved in activation of PLC
GRM7
Glutamate receptor involved in inhibition of cAMP
GLI3
Zinc finger transcription factor
MEF2C
Myocyte enhancer
PLA2R1
PLA2 receptor involved in clearance
PLCE1
Phospholipase that produces IP3 and DAG
ARHGEF3
Activates 2 Rho GTPases, brain expressed in UniGene
Abbreviations: cAMP, cyclic adenosine monophosphate; cGMP, cyclic guanosine monophosphate; DAG, diacylglycerol; GTPases, guanosine triphosphatases; IP3, inositol triphosphate; PKA, protein kinase A; PLA2, phospholipase A2; PLC, phospholipase C. Molecules driving the association with the CRH signaling pathway are also driving association with the PLC signaling pathway (eFigure 4 in Supplement), including PLC γ, IP3 receptor, and myocyte enhancer factor 2. In addition, PLC may produce diacylglycerol and IP3. Lithium blocks the conversion of inositol phosphate to inositol and leads to the accumulation of IP3. The IP3 system has been related to lithium therapeutic activity. 34 Williams et al 35 proposed that inositol was involved in the therapeutic actions of valproic acid and carbamazepine as well as lithium. The endothelin 1 signaling pathway (eFigure 6 in Supplement) includes several phospholipases with major activity on second messenger systems and intracellular metabolism in addition to PLC. These are phospholipase A2, which activates the arachidonic acid cascade, and phospholipase D, which hydrolyzes phosphatidylcholine to produce phosphatidic acid and choline, the precursor for acetylcholine. These phospholipases are important not only in endothelial cells but also in neuronal cells. They may play a role in inflammatory responses, 36 and inflammation has been implicated in the pathophysiology of BP in numerous studies.
37
As the major excitatory neurotransmitter in the mammalian central nervous system, glutamate signals are relayed by ionotropic and metabotropic (G-protein-coupled) receptors from the cell membrane through various second messenger systems (eFigure 5 in Supplement). One of the strongest candidate gene findings in BP has been the association with D-amino acid oxidase activator (DAOA, also known as G72), which deactivates N-methyl-D-aspartate receptors by degrading serine.
38 A functional variant in this gene has been associated with reduced cortical thickness in schizophrenia. 39 Riluzole, a glutamate-modulating agent, has shown preliminary antidepressant results in an open-label study in combination with lithium in patients with BP in the depressed state. 40 We believe that our method of pathway identification has certain advantages. We consider evidence from multiple GWAS and deliberately focus on associations that are modest but consistent, a strategy that has proven successful in prior studies. 4, 8 We correct for gene size using a permutation procedure to calculate empirical P values. We also incorporate FDR into our pathway assessment procedure. Our results are readily interpretable at the gene and pathway levels. To our knowledge, our data set, which includes most of the PGC1 and PGC2 BP data sets, incorporates and expands on all GWAS data sets used in previously published BP pathway studies, except for the PGC article itself. 4 We note an emphasis on glutamate mechanisms, 10, 14 hormonal action, 11 and calcium signaling 4 in our results as well as others. One area not emphasized in our results but noted in others 12, 14 is that of mechanisms of neuronal growth and cell adhesion molecules. This area is prominent in the genes that overlap with gene expression results (see earlier) in this study. Our study has limitations. Our method identifies genes with abnormalities in cis regulation (within the gene or promoter) in BP but not genes with abnormalities in trans regulation (regulatory changes at distant sites). Future studies should be able to use methods and databases that will include trans-regulated abnormalities. We have chosen a threshold (≥2 SNPs at P < .05 in 3 of 4 data sets) that minimizes false-positive results and includes a sufficient number of true-positive results to support pathway detection. This threshold provides better power to detect larger genes than smaller genes (<25-50 kb), which are underrepresented in the list of 226 we have used for tagging pathways. The pathways themselves, however, include small and medium-sized genes as well as larger genes. Canonical pathways, while having the advantage of providing a predetermined gene list, are based on the existing neurobiological literature as curated by Ingenuity Systems Inc. As data sets expand and other pathway sources (KEGG, GO) are used, we expect additional biological mechanisms to be discovered and present results to be refined. It is possible that some associated variants may be markers for true susceptibility variants in nearby genes. We have minimized (but not eliminated) this possibility by using GSEA-SNP, which tests all the SNPs in each selected gene, not just those that passed the threshold for gene identification. Functional studies and insights from systems biology will be required to determine which genes and pathways are truly relevant to BP and what mechanisms are involved. The comparison between results from GWAS and gene expression studies using postmortem brain samples must be interpreted carefully because of differences in subject ascertainment and probable nongenetic causes of some gene expression changes.
Conclusions
In summary, 17 pathways were identified in an initial screen of GWAS data from 4 samples totaling 5253 BP cases and 6874 controls, of which 6 pathways were verified in an independent set of 3507 cases and 4889 controls. The identification of these pathways was driven by genes involved in hormone regulation, calcium channel genes, genes involved in second messenger systems, and glutamate receptor genes. Nine genes involved in the pathway identification were also dysregulated in brain samples from patients with BP. In addition to the functions described earlier, these included genes that are involved in neuronal development.
